sorafenib has been researched along with ketoconazole in 8 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ketoconazole) | Trials (ketoconazole) | Recent Studies (post-2010) (ketoconazole) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 6,202 | 706 | 1,269 |
6,520 | 730 | 5,251 | 149 | 0 | 120 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 4 (50.00) | 24.3611 |
2020's | 3 (37.50) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Cihon, F; Gallentine, M; Lathia, C; Lettieri, J; Radtke, M; Sundaresan, P | 1 |
Abdel-Maksoud, MS; Alach, NN; Anbar, HS; El-Gamal, MI; El-Gamal, R; Oh, CH; Sbenati, RM; Shehata, MK; Tarazi, H; Zaraei, SO | 1 |
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
Abu Rabah, RR; Al Shamma, SA; Al-Tel, TH; Anbar, HS; El-Gamal, MI; Elgendy, SM; Omar, HA; Sebastian, A; Shehata, MK; Sultan, S; Tarazi, H; Vunnam, S; Zaraei, SO | 1 |
2 review(s) available for sorafenib and ketoconazole
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
6 other study(ies) available for sorafenib and ketoconazole
Article | Year |
---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.
Topics: Adult; Antifungal Agents; Benzenesulfonates; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
Topics: Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Imidazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, ErbB-4; Structure-Activity Relationship; Thiazoles | 2021 |
Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship | 2022 |